XML 61 R50.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue Recognition - Effect on Statements of Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jun. 28, 2019
Jun. 29, 2018
Jun. 28, 2019
Jun. 29, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Revenue $ 4,010,761 $ 3,971,606 $ 12,276,097 $ 11,876,035
Costs and Expenses:        
Cost of services provided 3,594,978 3,526,293 11,029,382 10,611,532
Depreciation and amortization 148,779 156,934 447,408 443,646
Selling and general corporate expenses 78,185 101,715 270,600 282,327
Costs and Expenses 3,821,942 3,784,942 11,591,081 11,337,505
Operating income 188,819 186,664 685,016 538,530
Gain on sale of Healthcare Technologies     (156,309) 0
Interest and Other Financing Costs, net 82,220 89,776 249,375 256,562
Income Before Income Taxes 106,599 96,888 435,641 281,968
Provision (Benefit) for Income Taxes 23,535 24,172 72,589 (110,904)
Net income 83,064 72,716 363,052 392,872
Less: Net income attributable to noncontrolling interest 109 139 60 442
Net income attributable to Aramark stockholders 82,955 $ 72,577 362,992 $ 392,430
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Revenue (80,343)   (260,433)  
Costs and Expenses:        
Cost of services provided (82,624)   (265,821)  
Depreciation and amortization 5,173   13,072  
Selling and general corporate expenses 0   0  
Costs and Expenses (77,451)   (252,749)  
Operating income (2,892)   (7,684)  
Gain on sale of Healthcare Technologies     0  
Interest and Other Financing Costs, net 0   0  
Income Before Income Taxes (2,892)   (7,684)  
Provision (Benefit) for Income Taxes (749)   (1,990)  
Net income (2,143)   (5,694)  
Less: Net income attributable to noncontrolling interest 0   0  
Net income attributable to Aramark stockholders (2,143)   (5,694)  
Calculated under Revenue Guidance in Effect before Topic 606        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Revenue 3,930,418   12,015,664  
Costs and Expenses:        
Cost of services provided 3,512,354   10,763,561  
Depreciation and amortization 153,952   460,480  
Selling and general corporate expenses 78,185   270,600  
Costs and Expenses 3,744,491   11,338,332  
Operating income 185,927   677,332  
Gain on sale of Healthcare Technologies     (156,309)  
Interest and Other Financing Costs, net 82,220   249,375  
Income Before Income Taxes 103,707   427,957  
Provision (Benefit) for Income Taxes 22,786   70,599  
Net income 80,921   357,358  
Less: Net income attributable to noncontrolling interest 109   60  
Net income attributable to Aramark stockholders $ 80,812   $ 357,298